+44 7868 792050
OnPoint CRO, USA
Posters & Accepted Abstracts: J Clin Trials
Clinical research is critically important to develop new treatments and substantial regulations help to protect patient safety and data integrity. However, poor patient recruitment continues to increase clinical study costs and timelines. In the United States, the pharma/CRO industry has reacted by developing tactics to engage patients directly and â�?�?matchâ�? them with â�?�?qualifiedâ�? investigators (i.e., physicians with a successful track record in clinical research), yet macro-level data do not suggest this has had positive impact. To fix the problem, industry must acknowledge and address the shortage of physicians willing/able to become involved with clinical research (and the business-related reasons for this) and that the â�?�?matchmakingâ�? approach incorrectly assumes patients will be enthusiastic about seeing doctors other than their own. Boosting patient participation in studies; means increasing the number of physicians willing to serve as investigators. The industry can no longer depend on a free market approach in which the best potential research sites voluntarily invest in the infrastructure necessary to be successful, because quite simply, the benefits of doing so are uncertain and not enough to offset the many other regulatory and resource demands in todayâ�?�?s healthcare environment. This session will explore barriers to physician and patient participation in clinical research, the strengths and weaknesses of todayâ�?�?s normative approaches to investigator training/selection and potential solutions that the pharma/CRO industry must consider.